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Abstract 
Photoacoustic imaging (PAI) is an emerging tool that bridges the traditional depth limits of 
ballistic optical imaging and the resolution limits of diffuse optical imaging. Using the acoustic 
waves generated in response to the absorption of pulsed laser light, it provides non-invasive 
images of absorbed optical energy density at depths of several centimeters with a resolution 
of ~100 μm. This versatile and scalable imaging modality has now shown potential for 
molecular imaging, which enables visualization of biological processes non-invasively using 
systemically introduced contrast agents. Understanding the relative merits of the vast range 
of contrast agents reported, from small molecule dyes, through gold and carbon 
nanostructures, to liposome encapsulations, is a significant challenge. Here, we critically 
review the physical, chemical and biochemical characteristics of the existing photoacoustic 
contrast agents, highlighting key applications and present challenges for molecular PAI. 
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Introduction 
 
Molecular imaging aims to visualize and quantify biological processes at the 
molecular and cellular level in a non-invasive manner, providing an opportunity to detect, 
stage, predict and monitor the development of disease. As early as the 17th century, Anton 
van Leeuwenhoek and Robert Hooke used light to visualize cells. Light experiences 
significant scattering as it passes through tissue, which requires an inherent tradeoff 
between depth of penetration and spatial resolution. Microscopy and other techniques that 
utilize unscattered photons provide high resolution (~1 μm) images but only to a maximum 
depth of  ~1 mm in most tissues; diffuse optical techniques such as fluorescence and near 
infrared optical tomography that exploit multiply scattered photons can reach depths of 
several cm provided spatial resolution is sacrificed (>1 mm).1  
Photoacoustic imaging (PAI) is an emerging method that combines the high contrast 
of optical imaging with the high spatial resolution of ultrasound.2–5 Tissue heating due to the 
absorption of short laser pulses by endogenous chromophores or exogenous contrast 
agents produces broadband acoustic waves at MHz frequencies. These photoacoustic 
waves can be detected by ultrasound transducers at the tissue surface and reconstructed to 
form an image of the absorbed optical energy distribution2. Supplementary Fig. 1 and Note 1 
illustrate this process and explain the requirements for the image to represent absorbed 
optical energy. Since sound waves are less scattered in tissue than photons, PAI can push 
the traditional limitations of optical imaging. For example, when operating in the ‘near-
infrared (NIR) window’ (620 – 950 nm), tomographic PAI can reach a penetration depth of 
several centimeters with a resolution of the order of a few 100 µm, scaling to < 100 µm 
resolution for shallower (<1 cm) penetration depths.3 
PAI is currently one of the fastest-growing molecular imaging techniques. It has 
rapidly been adopted for preclinical in vivo imaging in small animals for a range of disease 
indications. The prevailing application is in cancer research, where PAI has been explored 
for: primary tumor detection and molecular characterization6,7; therapeutic monitoring8; as 
well as for the identification and assessment of metastatic lymph nodes9.  
This review highlights the latest advances in exogenous contrast agents for 
molecular PAI. We introduce the considerations for in vivo molecular PAI, detail the physical, 
chemical and biochemical characteristics of available contrast agents, and provide an 
overview of the strengths and weaknesses of each approach. Given the widespread use of 
this technique in cancer research, we draw on this field for key examples of the application 
of molecular PAI. 
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Sources of endogenous contrast in PAI 
 
While the focus of this review is exogenous contrast agents, it is important to 
appreciate the capabilities of, and challenges presented by, background endogenous PA 
signals when performing molecular PAI.  
 
Intrinsic chromophores 
 
Endogenous PAI provides structural and functional information through light 
absorption by hemoglobin, lipids, water and melanin (Fig. 1a). Hemoglobin, which delivers 
oxygen throughout the body, experiences structural and electronic modifications upon 
oxygen binding (Fig. 1b). The resulting changes in the absorption spectrum (Fig. 1a) offer 
the prospect of measuring total hemoglobin concentration (Hbtotal) and oxygen saturation 
(sO2), important for studying tumor angiogenesis (Fig. 1c).
10,8 PAI can also map lipid 
distribution in vivo11 based on the absorption peaks at 930 and 1,210 nm (second overtone 
of abundant C-H bonds), while water can be identified based on the absorption peak at 975 
nm.12 Melanin is a ubiquitous natural pigment in skin, hair and eyes, with intense optical 
absorption, enabling sensitive characterization of primary melanoma13,14 and metastatic 
melanoma cells15. Intrinsic chromophores therefore provide access to only a limited range of 
biological processes and when performing molecular PAI, they represent the background 
absorption that must be overcome by contrast agent design. 
 
Genetically encoded chromophores 
 
Most cells in the body are invisible to PAI in the NIR window. Reporter gene imaging 
enables direct visualization of the location and level of gene expression, promoter activity 
and protein-protein interaction in vivo.16 Under the control of the promoter of the gene of 
interest, a reporter gene expresses proteins that either provide PA contrast directly or create 
a product that yields PA contrast (Fig. 2a).  
For example, the genetically encoded family of green fluorescent proteins (GFPs)17 
can provide direct contrast. The GFP family is, however, too blue-shifted for in vivo 
applications beyond virtually transparent organisms17 due to strong background absorption 
by endogenous chromophores at visible wavelengths (Fig. 1a). Unfortunately, the GFP-like 
red-shifted fluorescent proteins exhibit limited PA signal generation efficiency and 
photostability.18 The development of phytochrome-based NIR fluorescent proteins have 
begun to overcome these limitations19,20. Phytochromes are photosensory receptors that 
absorb light when they covalently bind a linear tetrapyrrole chromophore, such as biliverdin. 
Since biliverdin is an intermediate of normal mammalian heme metabolism, phytochromes 
are promising candidates as PAI genetic reporters for in vivo imaging. The first example in 
this class was iRFP, which can be excited at ~690 nm and shows good photo- and thermo-
dynamic stability in vivo.20 More recently, differential imaging of the on / off states in the 
reversibly switchable phytochrome BphP1 has been demonstrated. Excitation of the 
biliverdin-BphP1 complex with light in the range of 730-790 nm triggers the bound biliverdin 
to switch from trans to cis conformation (Fig. 2b), causing a change in the absorption 
spectrum towards 630-690 nm.21 The photoconversion was shown to reduce the impact of 
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background signals (Fig. 2c), improve detection sensitivity and increase penetration depth. 
Reversibly switchable phytochromes may therefore play a significant role in future studies. 
More widely explored transgenic approaches for PAI are based on enzymatic 
reporter genes. Here, the genetic product is an enzyme that produces a chromophore or its 
precursor. For instance, LacZ encodes the enzyme β-galactosidase, which metabolizes the 
transparent precursor substrate X-gal to produce a stable, dark-blue product.22 Dual-
wavelength PAI can detect tumor cells expressing lacZ up to 5 cm depth with high 
resolution.22 The lacZ-reporter gene system is limited, however, as X-gal must be locally 
administered and the metabolic product shows poor clearance. The tyrosinase-reporter gene 
system (Fig. 2d,e) introduces the key enzyme in melanin synthesis into non-melanogenic 
cells, hence does not require an exogenously administered substrate.23 Although the 
relatively featureless absorption spectrum of melanin (Fig. 1a) could make it hard to 
distinguish from intrinsic signals, in vitro and in vivo PAI of tyrosinase-expressing cells has 
shown high sensitivity23,24 and inducible systems can address potential toxicity concerns.25 
Despite their potential for signal amplification, enzymatic reporter systems are generally less 
desirable due to their dependence on substrate availability, which limits quantification.    
Reporter genes are suitable for applications where the cell or biological process of 
interest does not provide inherent PA contrast but use of an exogenously applied contrast 
agent is undesirable, for example, requiring repeated injections in longitudinal studies of 
tumor development. They are, however, subject to the same considerations as exogenous 
contrast agents in terms of desired photophysical properties, as discussed in the following 
sections. 
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Exogenous contrast agent considerations for molecular PAI  
 
To perform molecular imaging, a contrast agent (Fig. 3) must be composed of a 
signaling compound, which produces the signal for imaging, and a targeting moiety that 
enables the readout of a specific biological entity or process.   
 
Photophysical properties: signaling compounds  
 
The ideal signaling compound needs to exhibit the following characteristics: high 
molar extinction coefficient (Fig. 4), to maximize the amount of light absorbed; sharply 
peaked, characteristic absorption spectrum, to ensure unambiguous identification by spectral 
unmixing even at low molar concentrations (Supplementary Note 1); peak absorption in the 
NIR window (620 – 950 nm), to maximize penetration depth by avoiding the strong 
absorption of intrinsic chromophores (Fig. 1a); high photostability, to ensure that spectral 
features are not changed by light irradiation; low quantum yield, to maximize the non-
radiative conversion of light energy to heat; and efficient conversion of heat energy3 to 
produce acoustic waves. 
 
Biological properties: targeting and biocompatibility  
 
The targeted contrast agent must overcome circulatory and cellular barriers 
(Supplementary Fig. 2). Contrast agents will first interact with biomolecules in the 
bloodstream,26,27 where adsorption of biomolecules onto the surface will impact both immune 
responses and target binding.27,28 This needs characterization and consideration when 
interpreting biological results.  Furthermore, to reach their target, these agents typically need 
to pass out of the circulatory system. To extravasate, a maximum size limit of typically < 10 
nm is necessary, although for applications in cancer, contrast agents of up to 100 nm have 
been found to pass through the leaky vessels found in tumors29. Once in the tissue 
interstitium, passing the cellular barrier can be achieved by active targeting, for example to 
cell surface receptors30, transporters31, or metabolic enzymes32, or by relying on passive 
uptake through diffusion or endocytosis.  
 To facilitate active targeting, the biological target should be (over)expressed at an 
early stage of the disease and found at low levels in off-target tissues. Structures that can be 
used to achieve active targeting include small molecules, peptides and adhirons33, 
affibodies34, aptamers35 and proteins (Fig. 3). In particular, consideration must be given to 
biocompatibility, which refers here to minimizing toxicity (e.g. based on administration route 
and dose) and immune response (e.g. by reducing accumulation in non-targeted tissue), as 
well as optimizing elimination from the circulatory system and target tissue penetration.  
For example, combining small molecules such as sugars with small molecule dyes 
results in a small (<1 nm) contrast agent that can easily pass physiological barriers and clear 
rapidly through the kidneys, which reduces off-target accumulation and optimizes 
biocompatibility. Conversely, although proteins (e.g. monoclonal antibodies) show high 
target affinity and specificity, and thus display little cross-reactivity with healthy tissues, their 
larger size results in poorer tissue penetration and clearance, and immunogenicity is 
possible, resulting in poorer biocompatibility. Antibody fragments, including dia- and nano-
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bodies, are now being developed to address these challenges, since they are smaller in size 
but retain high affinity and selectivity.34,36 
For cancer research, the hyperpermeability of tumor vasculature combined with the 
lack of an intact lymphatic drainage may lead to ‘enhanced permeability and retention’ (EPR) 
of contrast agents of up to ~100 nm inside the tumor tissue without the need for targeting 
ligands.37 ‘Passive’ targeting based on the EPR has been demonstrated extensively in mice 
(Supplementary Tables 1-4) and recently the first studies have begun to emerge in 
humans38. Larger entities (> 100 nm) are typically not accumulated and will be cleared 
through the reticuloendothelial system.29 Passive targeting confounds attempts to perform 
targeted molecular imaging, as uptake is not specific to a biological process hence should be 
avoided as far as possible by contrast agent design.   
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Signaling compounds for molecular PAI 
 
Signaling compounds fall into three broad classes: small molecule dyes; metallic or 
semiconducting nanostructures; and organic nanostructures (Fig. 3). Supplementary Tables 
1-4 summarize PAI studies using different classes of compounds. Figure 4 enables direct 
comparison of two critical parameters for the ideal signaling compound: the specific 
extinction coefficients and peak absorption wavelengths for the different classes.  
Small molecule dyes 
 
Small molecule NIR dyes39 (Supplementary Table 1) are generally commercially 
available. The chemical basis of these dyes is a series of conjugated double-bonds and/or 
(mostly aromatic) ring systems. In these highly conjugated structures, electrons are 
delocalized, meaning less energy is needed for excitation. The well-defined energy gap 
between ground and excited states results in a distinct absorption peak (Supplementary Fig. 
3). Relaxation of the excited electrons can occur in radiative (fluorescence or 
bioluminescence) or non-radiative processes, dependent on the lifetime and electronic 
configuration of the excited states (Fig. 5a).40 For PAI, a large non-radiative relaxation is 
required so the quantum yield (referring to fluorescence emission) should be as low as 
possible.  
The first main class of NIR dyes used for PAI is the heptamethine cyanine dyes 
comprising two aromatic nitrogen-containing heterocycles linked by a heptamethine 
chain.41,42 An example is indocyanine green (ICG), an FDA approved dye with low toxicity. In 
aqueous solution, ICG has an absorption maximum at 780 nm and a relatively low quantum 
yield for fluorescence (0.027).43 Due to its inherent hydrophobicity, ICG exhibits high plasma 
protein binding and is used clinically as a blood flow contrast agent.44 ICG was rapidly 
applied in cancer research studies using PAI for identification of the closest ‘sentinel’ lymph 
node (SLN) in the lymphatic drainage from a tumor45, which is crucial for cancer staging. 
However, the hydrophobicity of ICG (and other small molecule dyes) can result in significant 
concentration- and environment- dependent changes in optical properties (Fig. 5b)46. Also, 
functionalization and targeting chemistry of ICG is challenging; unmodified ICG is therefore 
not ideal for molecular PAI47,48 and alternative heptamethine cyanine dyes have been 
exploited for this purpose (Supplementary Table 1). 
Squaraines are the second main class of NIR dyes that could be employed for 
molecular PAI. They are characterized by an electron deficient central 4-membered ring 
often conjugated to two electron-donating groups to generate a donor-acceptor-donor form, 
which increases the delocalization of the electrons. The optical properties can be tuned by 
varying donor strengths to produce sharp absorption bands in the NIR range.49 Despite good 
optical properties and photostability, squaraines are often limited by insolubility, aggregation 
and chemical reactivity.50,51 In PAI they have only been used in conjunction with 
phospholipids, albumin or polymers owing to poor solubility.52–54 Additional dye classes with 
fewer examples in PAI are rhodamines and azo dyes. Rhodamines are characterized by a 
xanthene core unit with diakylamino groups and have high photostability55. Azo dyes 
Methylene Blue (MB, 664 nm) and Evans Blue (EB, 620 nm) have been used for PAI, but 
are limited by relatively blue shifted absorption peaks56,57 and potential to cause 
photodamage under intense irradiation.58  
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Challenges associated with the use of small molecule dyes include: low molar 
extinction coefficient (< 3 × 105 M-1 cm-1); low solubility; and tendency to aggregate. It is 
possible to address some of these challenges chemically, by attaching hydrophilic groups, 
introducing triplet-state quenchers59 and integrating stabilizing groups60. Additionally, 
variations in the chemical design, such as varying the size of the conjugated system, 
attaching electron donating / withdrawing groups, allow tailoring of the spectral range. Their 
chemical flexibility also facilitates the creation of ‘smart’ contrast agents (Section ‘Emerging 
concepts in molecular PAI’), which can in part compensate for their low molar extinction 
coefficient by minimizing the influence of the background signal from endogenous 
chromophores. 
Most small molecule dyes must be actively targeted to gain specificity. A common 
target for detection and characterization of solid tumors in preclinical research is the cell 
surface epidermal growth factor receptor (EGFR), which is frequently overexpressed. 
Hudson et al explored the potential of molecular PAI for detecting EGFR-expressing tumors 
in a mouse model of pancreatic cancer (depths >5 mm) by conjugating the epidermal growth 
factor (EGF) protein to the rhodamine NIR dye CF-750 (Fig. 5c).61 The absorption spectrum 
of CF-750 was not significantly altered by the bioconjugation to EGF and the probe signal 
could be clearly distinguished from background by multi-wavelength PAI, providing a non-
invasive readout of EGFR expression. Importantly, there was no noted toxicity.  
In spite of their photophysical limitations, small molecule dyes remain good 
candidates for molecular PAI in the preclinical study of extravascular targets due to their 
small size and favorable biocompatibility. 
 
Nanostructures 
 
Nanoparticles (NPs) embody the largest class of contrast agents for molecular PAI. 
They possess high chemical, physical and biochemical flexibility, as well as significantly 
increased molar extinction coefficients compared to small molecule dyes. NPs exist in 
different materials, shapes and sizes (< 1000 nm, usually ~10-100 nm), and have tunable 
surface properties, reactivity and optical characteristics. Their large surface area means a 
large number of targeting moieties can be attached per particle, increasing target-binding 
probability. However, due to their larger size, NPs often accumulate in the reticuloendothelial 
system for long time periods, yielding poorer biocompatibility. Furthermore, the 
reproducibility, purification, and quantification of homogeneous, well-defined NPs remains 
challenging.62 Details of common synthesis routes for all nanostructures and nanomaterials 
demonstrated for PAI can be found in Supplementary Notes 2 and 3. 
Gold 
 
The main focus of research into metallic nanoparticles for molecular PAI has been on 
gold, owing to its unique optical and physicochemical properties, relatively inert nature, and 
prior use in humans. In addition, gold forms strong gold-thiolate bonds that enable covalent 
surface modifications for optimizing biocompatibility (e.g. poly(ethylene glycol) (PEG) 
functionalization)63, stability (e.g. silica encapsulation)64 and active targeting. 
The optical properties of gold nanoparticles (GNPs) arise from the ‘localized surface 
plasmon resonance’ (LSPR) phenomenon. The conduction electrons of a GNP oscillate 
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relative to the core when exposed to light of an appropriate wavelength (Fig. 6a). This state 
is referred to as plasmon.65 Plasmons convert a significant part of the oscillation energy into 
heat detectable with PAI. The key advantage of GNPs for PAI signal generation is that they 
essentially act as a macroscopic dipole, leading to an extinction coefficient several orders of 
magnitude higher than small molecule dyes (extinction scales ~ volume^3).66 GNPs show 
the highest extinction coefficient in the NIR range and high PA conversion efficiency.  
The frequency of the LSPR determines the peak absorption wavelength of the GNP, 
which can be tuned based on: surface-to-volume ratio; polarization modes; edge / vertex 
number and ‘sharpness’ of the GNP. Therefore, in addition to spheres, a wide range of GNP 
shapes, including stars, tripods, plates and prisms have emerged (Supplementary Table 2). 
A key example of tuning is found in gold nanorods (GNRs), whose intense and narrow LSPR 
absorption bands in the NIR are tuned by varying their aspect ratio (Fig. 6b). GNRs are 
commonly encapsulated in silica, which reduces gold interfacial thermal resistance with the 
solvent, which improves PA conversion efficiency64,67 and photostability.68 Another example 
is the use of hollow gold nanostructures, such as gold nanocages (GNCs) and gold 
nanoshells (GNSs) that can also encapsulate cargo such as drugs within their porous walls. 
The LSPR frequency can be conveniently tuned not only based on size but also on shell 
thickness (thinner = red shift) (Fig. 6c).69,70 These simple methods for tuning the 
characteristic spectral shape and peak wavelength are highly advantageous for molecular 
PAI. 
In diseases with a leaky vasculature, like cancer, GNPs can be accumulated via the 
EPR effect.71 Actively targeting the angiogenic tumor vasculature (in contrast to quiescent 
surrounding vessels) provides a tumor specific readout that circumvents the physiological 
barrier of extravasation into the tissue. The tripeptide arginine-glycine-aspartic acid (RGD) 
and its derivatives are widely used to target the αvβ3 integrin on angiogenic vessels. All 
studies to date used a bifunctional PEG linker to conjugate the GNP with the RGD derivative 
(Supplementary Table 2). Studies with larger RGD-modified GNPs suffer from high 
accumulation in the reticuloendothelial system and slow tumor accumulation of at least 6 
h.30,72 This is unfavorable in terms of biocompatibility, as it renders the reticuloendothelial 
system organs prone to oxidative damage via free radical formation.73 These limitations were 
recently overcome using small gold tripods (< 20 nm) conjugated to the RGD derivative 
cyclic Arg-Gly-Asp-D-Phe-Cys via a PEG linker (Fig. 6d, e).74 PAI results were verified with 
64Cu PET. Encouragingly, RGD-gold tripods showed rapid accumulation in a U87MG glioma 
within 2 hours without systemic toxicity.  
Targeting GNRs to extravascular cell surface receptors has been demonstrated 
using antibody conjugation. Due to their relatively narrow spectrum, GNRs tuned to absorb 
at a range of different peak wavelengths can be conjugated to multiple targets, which has 
enabled multiplexed characterization of tumor EGFR and human epidermal growth factor 
receptor 2 (HER2) expression7 allowing characterization of heterogeneous tumors and 
specific tracking of combination therapies. It remains to be seen whether the use of GNPs in 
reaching extravascular targets generalizes across disease types and to applications in 
healthy tissue with intact vasculature.  
GNPs possess the most flexible photophysical properties of the compounds 
reviewed. Easy and stable functionalization of GNPs can be made via gold-thiolate bonds, 
suitable for attachment of a range of targeting moieties and further signaling compounds for 
multimodal imaging. Their associated spectral flexibility makes GNPs highly suitable for 
multiplexed imaging of different targets within the same tissue. Nonetheless, interaction of 
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the GNPs reviewed here within the vascular and tissue compartments depends on their size, 
shape, charge and synthesis route. Biocompatibility in vivo therefore needs to be more 
systematically addressed through longer term toxicity studies for individual nanostructures. 
 
Carbon  
 
Carbon forms different allotropic structures: carbon nanotubes, graphene-based 
nanomaterials and nanodiamonds (Supplementary Table 3). All three classes can be 
synthesized to possess an intrinsic absorption in the NIR range (Fig. 7a,b, Supplementary 
Fig. 4 and Note 2). Despite possessing a lower molar extinction coefficient than gold, carbon 
nanoparticles (CNPs) hold significant potential for molecular PAI due to their flexibility of 
synthesis and functionalization. Of particular interest is the wide variety of covalent75–78 as 
well as non-covalent modifications with small molecules (dyes79, drugs80, surfactants81), 
polymers79 and biomolecules82 that can be used for: targeting; increased solubility and 
stability83; improved signaling properties84 or increased specificity79. The absorption spectra 
of CNPs tend to be relatively broad in the NIR range, presenting a challenge for spectral 
unmixing in molecular PAI, but the attachment of NIR dyes can circumvent this limitation 
(Supplementary Fig. 5).  
  The majority of molecular PAI studies using carbon have been performed using 
single-walled carbon nanotubes (SWNT). SWNTs can be visualized as cylindrically rolled-up 
graphene sheets with diameters of 1-3 nm and lengths up to centimeters (Fig. 7a).85 
Semiconducting SWNT can exhibit numerous optical absorption peaks (Fig. 7a,b). The 
absorption peaks are defined by narrow energy ranges where many electronic states are 
available (referred to as van Hoff singularities, Fig. 7b). The electronic, and thus optical, 
properties are tunable by changing the tube structure, for example, diameter and chirality. 
The band gap generally varies inversely with the diameter, but many open questions remain 
regarding the complex photophysics of SWNTs.86,87 
 Molecular targeting of the αvβ3 integrin for angiogenesis imaging has also been 
achieved in multiple studies of CNPs using RGD-peptides attached to SWNT.79,88–90 De la 
Zerda et al conjugated RGD peptides through PEG grafted phospholipids to SWNT. In vivo 
evaluation found a strong PAI signal in the tumor for SWNT-RGD compared to only weak 
signals (via passive EPR uptake) for non-targeted SWNTs (Fig. 7c).88 Attachment of NIR 
dyes to the surface of the nanotubes achieved substantial PA contrast and sub-nanomolar 
sensitivities in mice compared to plain SWNT.79,90 The underlying mechanism of the 
enhancement was not established, but quenching effects between the dyes and SWNT may 
play a part. It should be noted that photobleaching can occur due to the instability of the 
dyes associated with these constructs.  
SWNTs have also been specifically targeted to tumors overexpressing the cell 
surface glycoprotein CD44 by coating them with a hyaluronic acid-based biosurfactant.  The 
coating is degraded by hyaluronidases overexpressed in cancer cells. Further labeling of the 
hyaluronic acid-unit with a fluorescent dye was used to provide validation of the selective 
CD44 receptor uptake using PAI and fluorescence imaging83 illustrating controlled SWNT 
delivery. 
Although CNPs are generally limited by their broadband absorption profile and low 
molar extinction coefficient (similar to dyes), they offer high photostability and versatile 
routes for functionalization and tailoring of spectral properties. Limited investigations of 
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biocompatibility suggest that as with GNPs, surface modification, size, shape and synthesis 
method play a role.91 Several studies have reported cytotoxicity and inflammatory potential 
of SWNTs92,93, although this can be significantly reduced by functionalization.94,95 On the 
contrary, emerging evidence suggests that nanodiamonds exhibit high biocompatibility96,97,98. 
Significant future effort is needed to better understand CNP photophysics and potential for 
biocompatibility. 
Organic Nanostructures 
 
An exciting recent development in molecular PAI is the use of polymer nanoparticles 
and encapsulations (Supplementary Table 4). They have high structural and functional 
flexibility (composition, shape, charge, size) and can act directly as signaling compounds, 
enhance biocompatibility of other signaling compounds, or act as a foundation for activatable 
imaging probes in PAI. The most popular organic polymer structures for PAI contain either 
conjugated polymers or porphyrin related units (Supplementary Fig. 6), which directly absorb 
light. Their molar extinction coefficient sits between the small molecule dyes and GNPs (Fig. 
4), and while their absorption spectra may be broad, they usually exhibit an absorption peak 
in the NIR (Fig. 7d) and are relatively photostable. Furthermore, their chemically and 
physically stable polymeric platform provides the opportunity to attach specific targeting and 
therapeutic moieties (see Supplementary Note 2).  
 Polymer nanoparticles come in many different flavors. Conjugated polymers (CP) are 
macromolecular structures with a highly delocalized conjugated backbone (Supplementary 
Fig. 6a). The conjugated system is spread through the entire polymer backbone and the 
polymers are densely packed into NPs yielding much higher extinction coefficient and 
photostability than small molecule dyes. The optical properties (strongly dependent on the 
conjugated core) can be tuned by: adopting different backbone structures; combining 
different conjugated polymers; and controlling aggregation and surface functionalization.99–
101 As an example, polypyrrole NPs are advantageous for PAI due to intense NIR absorption, 
high photothermal conversion efficiency and photostability, without acute toxicity.102 They 
can be well dispersed in aqueous solution102 but lack functional groups for surface 
modification. Alternative CPs that can be enriched with functional units are being 
developed,103,104 characterized also by an alternating electron donor-acceptor structure that 
shifts the absorption spectrum towards longer wavelengths (Supplementary Fig. 6b). 
Compared with SWNTs and GNRs these have been shown to yield 4-fold higher PAI signal 
in vivo on a per mass basis, but lower than the GNRs when compared on a molar basis.104 
They can also act as ‘smart’ contrast agents (Section ‘Emerging concepts in molecular PAI’), 
for example, for in vivo real-time imaging of reactive oxygen species.104  
Alternatives to synthetic CPs are the naturally occurring porphyrins, aromatic 
macrocycles from heme and chlorophylls containing four pyrrolic units linked by methane 
(Supplementary Fig. 6a). While CPs often possess a broadband absorption profile, porphyrin 
NPs show a narrow absorption peak in the NIR, allowing a clearer identification in PAI (Fig. 
7d). The chemical characteristics of the porphyrin macrocycle offers architectural flexibility, 
which permits tuning of the optical properties (Supplementary Fig. 6b). As with uncoated 
CPNPs, unmodified porphyrins are insoluble. Lovell et al overcame this challenge by 
conjugating porphyrin to a phospholipid, which resulted in self-assembled porphysomes with 
a bilayer structure.105 The porphyrin molecules inside the porphysome create J-aggregates, 
red-shifting the absorption peak (Supplementary Fig. 6b), and causing fluorescence 
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quenching to yield a strong NIR PA signal.106,105 The porphyrin-lipid shell was also used for 
encapsulation of carboxyfluorescein, doxorubicin105 or fluorinated gases enabling multimodal 
PAI, ultrasound and fluorescence imaging.107,108 As natural products, poryphyrins and 
porphysomes would be expected to show high biocompatibility, but due to their relative 
immaturity as contrast agents, this has yet to be established in vivo.   
Other polymers lacking intrinsic optical absorption but showing favorable 
biocompatibility can incorporate signaling compounds through micellar or vesicular 
structures, which can also be used for targeted delivery of compounds. Gold nanobeacons 
are formed from small GNPs (2-4 nm) trapped within synthetic or natural amphilines, forming 
NPs 60–260 nm in size.109,110  Advantages of such formulations include improved 
photostability, biocompatibility, signal intensity and targeting ability, relative to the signaling 
compound alone. Disadvantages include the presently limited knowledge of how polymer NP 
structure and local signaling compound concentration influences PA signal generation, as 
well as the larger size of the encapsulation. 
Despite their early stage of development, polymers and encapsulations have been 
demonstrated in numerous passive targeting applications: imaging mouse brain 
vasculature102,111 and tumor sentinel lymph node identification104,112,105 as well as  primary 
tumor characterization113–115. Wang et al actively targeted folate receptor positive MCF-7 
breast cancer xenografts with poly(D,L-lactide-co-glycolide) (PLGA) lipid NP containing ICG 
for PA signal and folic acid for targeting (Fig. 7e); the fabricated NPs showed good stability, 
high folate-receptor targeting efficiency and good PA signal in vitro and in vivo (Fig. 7f).116 
Conjugation of polypyrrole NPs to the same target has also been demonstrated.103 
Biocompatibility in the latter study was assessed only in cells in vitro; studies in vivo were 
limited to evaluating biodistribution, which showed the expected involvement of the 
reticuloendothelial system in contrast agent clearance.103  
The stable polymeric platform provides exciting opportunities to attach not only active 
targeting moieties but also activatable functionalities for smart probes (Section ‘Emerging 
concepts in molecular PAI’). Given that this class of contrast agents is relatively new, 
detailed biocompatibility studies are still lacking to prove their potential for in vivo application 
in molecular PAI. Further work to develop biocompatible platforms with even higher NIR 
absorption and multifunctional capability is expected to appear in the coming years. 
Emerging concepts in molecular PAI  
 
Smart (or ‘activatable’) contrast agents elicit a prescribed signal change, such as a 
shift in the peak absorption wavelength, in response to a biological stimulus of interest. As 
well as increasing the range of possible molecular imaging targets, a key advantage of smart 
contrast agents is that they minimize the influence of the background signal from 
endogenous chromophores, hence offering the potential for high sensitivity of detection. 
Their dynamic response also facilitates the study of processes such as enzymatic activity in 
real-time. Although relatively few examples exist so far for PAI, targeting proteases including 
matrix metalloprotease6 and furin32 has proven popular. In such ‘smart’ contrast agents, the 
protease substrate (a short peptide) links a quencher (BHQ3) with either a fluorophore 
(Alexa750)6 or NP (CuS)117. PA images acquired at the peak wavelengths of the two 
absorbers both show strong signals before the contrast agent reaches the target. Inside the 
tumor microenvironment, proteases cleave the linker, leaving only one absorption peak after 
cleavage, yielding a highly specific imaging approach to quantify protease activity non-
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invasively. Undesirable toxicity in off-target tissues with high physiological protease levels 
has yet to be assessed. 
Using multi-modality contrast agents it is possible to image the same target with two 
or more approaches (overcoming weaknesses of each modality) or to readout multiple 
targets, building a more complete picture of the underlying biochemistry. Molecular imaging 
modalities can differ in sensitivity up to 6 orders of magnitude118 requiring a difficult 
compromise to satisfy the concentration requirements for each modality. While PAI has been 
combined with PET74 and/or MRI119,120 for whole body imaging to determine contrast agent 
biocompatibility, its natural partners are ultrasound and fluorescence imaging due to the 
acoustic detection and optical excitation paths. Several PA and contrast enhanced 
ultrasound (CE-US) contrast agents are available.9,108 Small molecule dyes used for PAI are 
also fluorescent, which can facilitate ex vivo validation of contrast agent biodistribution in 
whole organs and tissue sections.  
   
Outlook: Promise and future challenges  
 
 PAI is an exciting new modality that uses non-ionizing radiation to perform real-time 
imaging with high spatial resolution and penetration depth. A broad range of application 
areas for molecular PAI have been identified, including oncology, neuroscience and 
cardiovascular diseases; basic research studies and preliminary clinical trials have focused 
primarily thus far on detection, staging and therapeutic monitoring in cancer.  
Despite great progress in molecular PAI contrast agent development in recent years, 
several challenges must be overcome in order to facilitate uptake into basic research in the 
life sciences. It is crucial that researchers recognize the need for standardized reporting of 
experimental approaches, for example, with regard to the measured photophysical 
properties. Publications should report in detail their calculations of extinction coefficients on 
both a ‘per mass’ and ‘per mole’ basis, along with independent measurements of both optical 
and photoacoustic absorption spectra as a function of concentration and solvent. These data 
have a major impact on biocompatibility, since detection sensitivity in vivo is intrinsically 
linked to administered dose. Systematic chemical studies to improve solubility, stability and 
specific targeting capability are needed across all contrast agent classes, along with the 
development of reproducible, cost effective and scalable chemical syntheses and purification 
methods.  
With photophysical and chemical characteristics optimized, criteria related to 
targeting and biocompatibility must also be fulfilled. The large size of nanostructures relative 
to physiological barriers may limit their application to intravascular targets for molecular 
imaging applications beyond cancer. Methods for nanostructure self-assembly in vivo may 
overcome such limitations. To provide convincing evidence of active targeting, both intra- 
and extra-vascular, studies must include both cellular controls (e.g. knockdowns of the 
biological target) and physiological controls (e.g. blocking with competing ligands). Although 
the nanostructured materials reviewed here are often claimed to be inert, biocompatibility 
appears to be strongly dependent on the nanostructure size, shape and synthesis method 
used in their preparation. In future studies, biological interactions, immunogenicity, stability, 
circulation and target tissue retention must be characterized for individual nanostructures to 
define their safety profile; relying on general literature from the nanostructure class is 
insufficient. Assessment of biocompatibility at both the cellular (in vitro) and organismal (in 
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vivo) levels is needed, including blood sampling and tissue analysis to identify potential 
acute and chronic inflammatory and toxicity effects.  
With biocompatibility concerns addressed, molecular PAI then has to achieve 
technical and biological validation before acceptance as a routine tool. Technical validation 
requires assessment of precision (repeatability / reproducibility) and accuracy (ability to 
relate the imaging signal to the abundance of chromophore). Although there have been 
significant efforts relating to accuracy of PAI121, there remains a paucity of data relating to 
precision.  
Key to routine application of molecular PAI is biological validation of the sensitivity 
and specificity of the readout in relation to the target biological entity or process. Comparison 
between contrast agents would benefit from standardization (e.g. through the use of 
published recommendations122) with regard to the disease model, tumor sizes, time points 
and reported metrics. This review has also revealed the near ubiquitous use of simple 
animal models, including subcutaneous tumors. Immunodeficient nude mice are also used 
routinely, which avoid the impact of skin melanin on optical absorption and minimize 
interactions with the immune system. While these systems provide an acceptable proof-of-
concept, translation of findings into transgenic mouse models on immune competent 
backgrounds (e.g. C57BL/6) will ultimately be needed for widespread uptake of the 
technique in preclinical research.  
The exogenous contrast agents described here are still in the early stages of 
exploration, mostly demonstrated only in single ‘proof-of-concept’ studies. Opposing the 
current trend towards vast increases in the number of different signaling compounds 
available, we believe that to maximize impact in preclinical molecular imaging, it is crucial to 
better understand the photophysical and biological properties of the promising classes that 
have already been reported, to enable their routine use. Lessons learned from other areas of 
molecular imaging indicate that the field may accelerate by focusing development and 
commercial efforts on contrast agents that prove successful in rigorous studies of 
biocompatibility and achieve biological validation using realistic animal models of disease.  
The advantages of molecular PAI can be appreciated across diverse applications. 
Here, we have highlighted applications in: detection of angiogenic vasculature; evaluation 
heterogeneity in tumor cell receptor expression; and visualization of protease activity. 
Contrast agents that meet both the photophysical and biological requirements set out in this 
review are likely to emerge in the near future. Such agents could rapidly advance studies of 
targeted cancer therapies, perhaps even tracking immune cell infiltration and activation in 
tumor models at high resolution to advance our understanding of the mechanisms of action 
and resistance for immunotherapy.  
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Figure Legends for Main Text 
Figure 1. Photoacoustic imaging of endogenous chromophores. (a) Absorption spectra 
of the main endogenous chromophores: Oxyhemoglobin (HbO2), red line (150 gl
-1); 
deoxyhemoglobin (Hb), blue line (150 gl-1); water, black line123 (80% by volume in tissue); 
lipid, yellow lines124,125 (20% by volume in tissue); melanin, brown line (μa corresponds to that 
in skin); collagen, green line. Data from http://omlc.ogi.edu/spectra/. (b) The heme group is a 
strongly-absorbing iron containing aromatic porphyrin ring system that exists in different 
configurations before and after oxygen binding, which produce characteristic changes in the 
absorption spectrum. (c) PAI (λ=640 nm) of tumor vasculature showing the effect of the 
vascular disrupting agent OXi4503.8  
 
Figure 2. Photoacoustic imaging of genetically encoded chromophores. (a) Simplified 
schematic demonstration of a general enzymatic reporter gene construct. (b) Photoswitching 
chemistry of Biliverdin from the Pfr state to the Pr state, and vice versa, induced by NIR 
(~730 – 790 nm) and far-red (~630 – 690 nm) light respectively.21 (c) Deep PA computed 
tomography of a mouse U87 brain tumor expressing BphP1, with the surrounding 
vasculature show in grayscale. The tumor (in color) was ~3 mm beneath the scalp surface.21 
(d) Retroviral vector construct for stable transduction of cells for visualization of tyrosinase 
(Tyr) expression mammalian cells. (LTR: long terminal repeat, includes the promotor; SD: 
splice donor; : viral packaging signal, which directs the incorporation of vector RNA into 
virions; SA: splice acceptor; IRES: internal ribosome entry sites).23 (e) Serial longitudinal in 
vivo PA images of stably transduced Tyr-expressing K562 cells after subcutaneous injection 
into the flank of a nude mouse, illustrating sensitive detection of produced melanin with 
depth resolution afforded by PAI (spatial resolution <100 μm at up to 10 mm depth).23 
 
Figure 3. Assembly of molecular imaging contrast agents for PAI combining a 
signaling compound with a targeting ligand. Current strategies for the development of 
targeted contrast agents, are: the direct conjugation of signaling compounds with targeting 
ligands; encapsulation of signaling compounds (and targeting ligand) by nanostructures; or 
encapsulation (with targeting ligands) and synthesis of target-activatable signaling 
compounds. The targeting ligand and signaling compound should be compatible in their 
chemical, physical and biological properties. Examples of the relative advantages and 
disadvantages of each approach are indicated by +/-. 31,32,120,126,127 
 
Figure 4. Reported extinction coefficients of a selection of signaling compounds used 
for PAI. References for reported values are: peptide-grafted nanodiamonds84; methylene 
blue128; IC7-1-Bu129; CDnir7130; IRDye800CW, ICG (http://www.spectra.arizona.edu/); 
SiNc131; gold nanospheres132; SWNTs104; SPN1104; gold nanostar133; porphysome105; gold 
nanorod134; gold nanopopcorn135; conjugated polymer NP104; cellulose NP113; gold 
nanocages71; PSS-coated gold nanorods136; gold nanocubes137; and gold nanoshells138.  
represents the peak absorption wavelength. 
 
Figure 5. Optical properties of near infrared (NIR) small molecule dyes and application 
for imaging the extravascular target epidermal growth factor receptor (EGFR) in 
pancreatic cancer. (a) General Jablonski diagram showing energetic transitions for an NIR 
dye after optical excitation. (b) Example absorption spectra of indocyanine green (ICG) in 
water and plasma in different concentrations, showing the significant impact of 
environmental conditions on spectral properties of NIR dyes, which can be challenging for 
PAI (spectra data used from University of Arizona http://www.spectra.arizona.edu/). (c) 
Multispectral optoacoustic tomography (MSOT) of mouse S2VP10L pancreatic 
adenocarcinoma at 7 days post implantation using EGF-CF-750 at 6 hours post-injection 
(Courtesy: Prof. L McNally).  
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Figure 6. Optical properties of gold nanoparticles (GNP) and application for imaging 
the intravascular target α
v
β
3
 integrin in glioma. (a) Localized surface plasmon resonance 
(LSPR) of spherical GNP and GNRs: electromagnetic waves induce plasmons, which can 
decay radiatively via re-emitting photons (scattering) or non-radiatively (essential for 
PAI).139,140 (b) Surface plasmon absorption spectra of gold nanorods of different aspect 
ratios, showing the sensitivity of the strong longitudinal band to the aspect ratios of the 
nanorods ( lLPSR = longitudinal LSPR; tLSPR = transverse LSPR). In comparison to GNR, 
gold nanospheres (grey line) show one absorption peak in green spectral range 141 (c) 
Surface plasmon resonance frequency of gold nanoshells, tuned to the NIR range by varying 
the shell thickness relative to the core size.142 (d) PAI and ultrasound imaging of U87MG 
tumors in nude mice with intravenously injected α
v
β
3
 integrin targeted gold tripods.74 (e) 
Chemical structure and UV-Vis spectroscopic profile α
v
β
3
 integrin targeted gold tripods.74 
 
Figure 7. Assembly and optical properties of single walled carbon nanotubes (SWNTs) 
and conjugated polymer nanoparticles (CPNPs), with applications in molecular 
imaging. (a) Schematic honeycomb structure of a graphene sheet, which can be rolled up 
from lattice point (0,0) to (n,m) along a chiral (roll-up) vector to form SWNT; the chiral vector 
length indicates the circumference/diameter of the tube and the chiral angle (α) the tilt 
between the hexagonal lattice and that vector. Depending on the diameter and twist the 
SWNT can be semiconducting (zigzag, blue n,m numbers) or metallic (armchair, red n,m 
numbers). Schematic illustration of the density of states (DOS) for semiconducting SWNT. (k 
= wavevector, S11/22 = first/second energy transition). (b) UV-vis-NIR absorption spectra of 
SDS-suspended HiPco SWNT showing S11 and S22 regions. Resolved peaks correspond to 
various (n, m) structures.143 (c) Difference images (2 h postinjection – pre-scan) for ICG-
labeled SWNT targeting U87MG glioma tumors.144 (d) Schematic of hybrid nanoparticles 
with a lipid monolayer shell and biodegradable polymer core (PLGA), which contain ICG for 
PA signal and DSPE-PEG-FA for targeting of folic acid (FA). (e) Absorption spectra of: a 
targeted conjugated polymer nanoparticle (CPNP, green line, structure shown in b and c) 103; 
porphyrin based NPs encapsulating perfluorocarbon gas (red line)108; FA-ICG-PLGA-lipid 
polymer nanoparticle (dark blue line)116; and ICG (light blue, dashed line). (f) Imaging of 
MCF7 breast tumors using hybrid FA-ICG-PLGA-lipid nanoparticles shows tumor uptake at 
24 hours post injection through the EPR effect (left), which is further enhanced by folic acid 
targeting (right). 116 
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